Search | Novo Nordisk

Primary manuscript

20th November 2018

Ranges and Drivers of Risk Associated With Sports and Recreational Activities in People With Hemophilia: Results of the Activity-Intensity-Risk (AIR) Consensus Survey of US Physical Therapists

Hernandez G, Baumann K, Knight S, Purrington H, Gilgannon M, Karelus M, Newman J, Tobase P, Mathew S Cooper DL. Ranges and Drivers of Risk Associated With Sports and Recreational Activities in People With Hemophilia: Results of the Activity-Intensity-Risk (AIR) Consensus Survey of US Physical Therapists. Haemophilia. 2018;24(S7):5-26.

Review article

19th November 2018

Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic

Jain S, Donkin J, Frey M, Peltier S, Gunawardena S, Cooper DL . Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic. J Blood Med. 2018;9:211-218.

Abstract

15th November 2018

Use of turoctocog alfa for less frequent prophylaxis in selected patients has comparable efficacy with the overall prophylaxis cohort in guardian 2

Matytsina I, Korsholm L, Tiede A, Janic D, Ozelo M, Santagostino E. Use of turoctocog alfa for less frequent prophylaxis in selected patients has comparable efficacy with the overall prophylaxis cohort in guardian 2. Associazione Italiana Centri Emofilia - 2018 Annual Conference. 2018.

Oral presentation

8th November 2018

Use of turoctocog alfa for less frequent prophylaxis in selected patients has comparable efficacy with the overall prophylaxis cohort in guardian 2

Santagostino E, Tiede A, Janic D, Ozelo M, Korsholm L, Matytsina I. Use of turoctocog alfa for less frequent prophylaxis: results from guardian 2. Societa Italiana per lo Studio dell'Emostasi e della Trombosi - XXV National Congress.

Primary manuscript

8th November 2018

Reliability and Validity of Patient-Reported Outcome Instruments in US Adults with Hemophilia B and Caregivers in the B-HERO-S Study

Buckner TW, Sidonio R, Guelcher C, Kessler C, Witkop M, Clark D, Owens W, Fridman M, Iyer N, Cooper DL. Reliability and Validity of Patient-Reported Outcome Instruments in US Adults with Hemophilia B and Caregivers in the B-HERO-S Study. Eur J Haematol. 2018.

Abstract

8th November 2018

Nonacog Beta Pegol for prophylactic treatment of children with hemophilia B: Up to 3.5-year data from the paradigm5 clinical trial

Kearney S, Santagostino E, Carcao M, Abdul Karim F, Taki M, Lu M-Y, Garly M-L, Zak M. Nonacog Beta Pegol for prophylactic treatment of children with hemophilia B: Up to 3.5-year data from the paradigm5 clinical trial. Societa Italiana per lo Studio dell'Emostasi e della Trombosi - XXV National Congress. 2018.

Abstract

8th November 2018

Use of turoctocog alfa for less frequent prophylaxis in selected patients has comparable efficacy with the overall prophylaxis cohort in guardian 2

Tiede A, Janic D, Ozelo M, Santagostino E, Korsholm L, Matytsina I. Use of turoctocog alfa for less frequent prophylaxis in selected patients has comparable efficacy with the overall prophylaxis cohort in guardian 2. Societa Italiana per lo Studio dell'Emostasi e della Trombosi - XXV National Congress. 2018.

Abstract

31st October 2018

Product switching in hemophilia A: addressing patient concerns using turoctocog alfa data from the guardian™ clinical trial program

Kulkarni R, Seremetis S, Matytsina I, Kupesiz A. Product switching in hemophilia A: addressing patient concerns using turoctocog alfa data from the guardian™ clinical trial program. Turk Hematoloji Dernegi - 44th Ulusal Hematoloji Kongresi. 2018.

Poster

26th October 2018

Turoctocog alfa is stable during storage at 40°C and multiple sequences of temperature cycling

Kolla R, Brand-Staufer B, Wojtyniak Dahl P, Debes Johansen S, Nøhr AM. Turoctocog alfa is stable during storage at 40°C and multiple sequences of temperature cycling. Indian Society of Haematology and Blood Transfusion - 59th Annual Conference (Haematocon 2018). 2018.

Abstract

25th October 2018

Safety of Nonacog beta pegol (N9-GP): results from the paradigm clinical trials

Collins P, Carcao M, Simonsen M, Ehrenforth S, Mahlangu JN, Mancuso ME, Oldenburg J, Negrier C. Safety of Nonacog beta pegol (N9-GP): results from the paradigm clinical trials. Societe Algerienne d'Hematologie et de Transfusion Sanguine - 15 Congres National. 2018.

Abstract

25th October 2018

Safety of Nonacog beta pegol (N9-GP): results from the paradigm clinical trials

Collins P, Carcao M, Simonsen M, Ehrenforth S, Mahlangu JN, Mancuso ME, Oldenburg J, Negrier C. Safety of Nonacog beta pegol (N9-GP): results from the paradigm clinical trials. Societe Algerienne d'Hematologie et de Transfusion Sanguine - 15 Congres National. 2018.

Secondary manuscript

23rd October 2018

Evaluation of bleeding disorders in patients with Noonan syndrome: A systematic review

Nugent DJ, Romano AA, Sabharwal S, Cooper D. Evaluation of bleeding disorders in patients with Noonan syndrome: A systematic review. J Blood Med. 2018;9:185-192.

Poster

11th October 2018

Efficacy of on-demand treatment of bleeding episodes in hemophilia B patients with extended half-life N9-GP in pivotal trials: an in-depth analysis of treatment

Escobar M, Walsh C, Cooper D, Young, G. Efficacy of on-demand treatment of bleeding episodes in hemophilia B patients with extended half-life N9-GP in pivotal trials: an in-depth analysis of treatment. National Hemophilia Foundation - 70th Annual Meeting. 2018.

Poster

11th October 2018

Head-to-head pharmacokinetic comparisons of N9-GP with standard FIX and rFIXFc in patients with hemophilia B

Simpson M, Cuker A, Kulkarni R, Pruthi E, Moss J, Cooper D. Head-to-head pharmacokinetic comparisons of N9-GP with standard FIX and rFIXFc in patients with hemophilia B. National Hemophilia Foundation - 70th Annual Meeting. 2018.

Abstract

11th October 2018

Head-to-head pharmacokinetic comparisons of N9-GP with standard FIX and rFIXFc in patients with hemophilia B

Simpson M, Cuker A, Kulkarni R, Pruthi E, Moss J, Cooper D. Head-to-head pharmacokinetic comparisons of N9-GP with standard FIX and rFIXFc in patients with hemophilia B. National Hemophilia Foundation - 70th Annual Meeting. 2018.

Primary manuscript

8th October 2018

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

Eichler H, Angchaisuksiri P, Kavakli K, Knoebl K, Windyga J, Jiménez-Yuste V, Hyseni A, Friedrich U, Chowdary P. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184-2195.

Abstract

8th October 2018

Efficacy of on-demand treatment of bleeding episodes in hemophilia B patients with extended half-life N9-GP in pivotal trials: an in-depth analysis of treatment

Escobar M, Walsh C, Cooper D, Young, G. Efficacy of on-demand treatment of bleeding episodes in hemophilia B patients with extended half-life N9-GP in pivotal trials: an in-depth analysis of treatment. National Hemophilia Foundation - 70th Annual Meeting. 2018.

Review article

1st October 2018

Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management

Benson G, Auerswald G, Dolan G, Duffy A, Hermans C, Ljung R, Morfini M, Šalek S. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus. 2018;16:535-44.

Primary manuscript

28th September 2018

Evaluating the thrombin generation profiles of four different rFVIII products in FVIII-deficient plasma using FIXa and FXIa activation

Brophy DF, Martin EJ, Ninivaggi M, Mohammed BM, Barrett JC, Kuhn J, Nolte ME, Waters EK, Ezban M. Evaluating the thrombin generation profiles of four different FVIII products in FVIII deficient plasma using FIXa- and FXIa-activation. Haemophilia. 2018;24(5):815-822.

Review article

28th September 2018

Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia

Tiede A, Worster A. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. Ann Hematol. 2018;97(10):1889-1901.

Mechanism of action animation

27th September 2018

Concizumab mechanism of action: The face of haemophilia treatment is changing

Secondary manuscript

27th September 2018

Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm trials

Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matshushita T, Negrier C, Clausen WHO, Ehrenforth S, Young G. Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm trials. Haemophilia. 2018.

Review article

24th September 2018

Practical aspects of extended half-life products for the treatment of haemophilia

Lambert T, Benson G, Dolan G, Hermans C, Jiménez-Yuste V, Ljung V, Morfini M, Zupančić-Šalek S, Santagostino E. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295-308.

Review article

24th September 2018

Recommendations on multidisciplinary management of elective surgery in people with haemophilia

Escobar M, Brewer A, Caviglia H, Forsyth A, Jimenez-Yuste V, Laudenbach L, Lobet S, McLaughlin P, Oyesiku L, Rodriguez-Merchan C, Shapiro A, Solimeno L. Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia. 2018;24(5):685-833, e301-e390.

Oral presentation

16th September 2018

Real-world health utility scores from haemophilia patients in France and the UK

Lambert J, Carroll L, Benmedjahed K, Lee XY, Zak M and Debaecker B. Real-world health utility scores from haemophilia patients in France and the UK. XXXVII World congress of the International Society of Hematology.

Oral presentation

16th September 2018

Real-world health-related quality of life data from haemophilia patients in France and the UK

Lambert J, Debaecker B, Benmedjahed K, Lee XY, Zak M and Carroll L. Real-world health-related quality of life data from haemophilia patients in France and the UK. XXXVII World congress of the International Society of Hematology. 2018.

Primary manuscript

11th September 2018

GlycoPEGylated recombinant factor IX for Hemophilia B in context

Santagostino E, Mancuso ME. GlycoPEGylated recombinant factor IX for Hemophilia B in context. Drug Des Dev Ther. 2018;12:2933-2943.

Review article

6th September 2018

Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management

John Wilding, Nichan Zourikian, Matteo Di Minno, Kate Khair, Natascha Marquardt, Gary Benson, Margareth Ozelo, Cedric Hermans. Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. Obes Rev. 2018;19(11):1569-1584.

Animated publication summary

23rd August 2018

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A

Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184–2195.

Review article

20th August 2018

Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B

Adcock D, Strandberg K, Shima M, Marlar R. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in hemophilia A and B.Int J Lab Haematol. 2018;40(6):621-629.

Search our science

Search Results